The Hyderabad-based Sven Genetech Ltd, subsidiary of Jupiter Bioscience Limited, has developed in-house process capabilities for commercial manufacture of peptide based bulk actives, which it plans to commence from 2006-07.

Sven would specialize in products based on peptide chemistry. It would integrate the peptide value chain by leveraging on the raw material strength of Jupiter, thereby becoming the only company in the world with an end-to-end peptide business model.

Besides manufacture of peptides and peptide based forward integration products for use in the pharmaceutical industry, Sven also has a strong research focus on peptide chemistry with state of the art research facility and manpower resources.

The research would be focused in the areas of establishing new process capabilities in launching peptide-based drugs and formulations, undertake development of new initiatives in peptides through research associations and joint development programs.

Over the past four years, Sven has been engaged in development of process capabilities for several products that are precursors to new generation drugs in the fields of AIDS treatment, cardiology, oncology, immunology, endocrinology, vaccines and others. The company's core competence is in the areas of peptide chemistry, chiral chemistry, biochemistry and microbiology.

The company has an asset base of about Rs 263 million. The company recorded a revenue of Rs 95 million and achieved profit after tax of about Rs 8 million in 2004-05 from its range of peptide precursors. In the year 2006-07, the company plans to roll out its peptide based bulk actives and has also initiated its foray into formulations in the areas of OTC preparations and nutraceuticals. In addition, the company plans to enter the emerging area of recombinant peptides.